Brain cancer update

Brain cancer update July 12, 2024
Leanna Standish

IV CURCUMIN

AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma. Curcumin is the molecule present in turmeric root that has anticancer activity. Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells. We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth. Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY. Last year we presented our first results of IV curcumin in glioblastoma to the SWEDISH HOSPITAL NEUROLOGY SEMINAR and at the ONCOLOGY ASSOCIATION OF NATUROPATHIC ONCOLOGY annual meeting.

Currently, Drs. Jaffe, Anthony, and Standish are preparing a scientific manuscript for a medical journal that summarizes our findings.

LIQUID BIOPSY IS NOW AVAILABLE FOR BRAIN CANCER

AIMS Institute utilizes cutting-edge cancer genetic sequencing to help us understand the unique biology of each patient’s cancer. Liquid biopsy refers to a blood test that sequences the DNA in tumor cells that circulate in the blood. Until 2024 there has never been a liquid biopsy for brain cancer. Thanks to BILLION TO ONE a cancer gene company there is now a blood test for brain cancer. These blood tests help us know what the best treatment might be and also whether the current treatment is working for the patient.

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...